Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

An open-label trial of riluzole in patients with treatment-resistant major depression.

Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK.

Am J Psychiatry. 2004 Jan;161(1):171-4.

PMID:
14702270
2.

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.

Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK.

Biol Psychiatry. 2005 Feb 15;57(4):430-2.

PMID:
15705360
3.

Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.

Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH.

Biol Psychiatry. 2007 Mar 15;61(6):822-5. Epub 2006 Dec 4.

4.

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS.

Int J Neuropsychopharmacol. 2010 Feb;13(1):71-82. doi: 10.1017/S1461145709000169. Epub 2009 Mar 17.

5.

A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression.

McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, Ascher J.

J Clin Psychiatry. 2004 Feb;65(2):204-10.

PMID:
15003074
6.

A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.

Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC.

J Clin Psychiatry. 2011 Oct;72(10):1405-12. doi: 10.4088/JCP.09m05355gre.

PMID:
21367355
7.

Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.

Ivković M, Damjanović A, Jovanović A, Cvetić T, Jasović-Gasić M.

Psychiatr Danub. 2009 Jun;21(2):187-93.

8.

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.

Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H.

Depress Anxiety. 2010 Oct;27(10):964-76. doi: 10.1002/da.20740.

PMID:
20734365
9.

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study.

Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ.

J Clin Psychiatry. 2007 Jul;68(7):1071-7.

PMID:
17685744
10.
11.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
12.

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH.

Biol Psychiatry. 2005 Sep 1;58(5):424-8.

PMID:
15993857
13.

Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C.

J Clin Psychiatry. 2006 Nov;67(11):1767-75.

PMID:
17196058
14.

Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study.

Anderson IM, Sarsfield A, Haddad PM.

J Affect Disord. 2009 Sep;117(1-2):116-9. doi: 10.1016/j.jad.2008.12.016. Epub 2009 Jan 25.

PMID:
19171384
15.

[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].

Azorin JM, Llorca PM, Despiegel N, Verpillat P.

Encephale. 2004 Mar-Apr;30(2):158-66. French.

PMID:
15107719
16.

Riluzole augmentation for treatment-resistant depression.

Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH.

Am J Psychiatry. 2004 Nov;161(11):2132. No abstract available.

PMID:
15514421
18.

Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.

van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group.

J Clin Psychiatry. 2009 Feb;70(2):223-31. Epub 2008 Dec 30.

PMID:
19200421
19.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
20.

Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.

Schüle C, Baghai TC, Eser D, Hecht S, Hermisson I, Born C, Häfner S, Nothdurfter C, Rupprecht R.

World J Biol Psychiatry. 2007;8(2):112-22.

PMID:
17455104

Supplemental Content

Support Center